Canadian International Pharma Corp. Closes Non-Brokered Private Placement

News Release No: 17-05

Trading symbols: TSX-V - NEX: CIP.H

Canadian International Pharma Corp. Closes Non-Brokered Private Placement

West Vancouver, British Columbia, July 28, 2017 – Canadian International Pharma Corp. (the “Company” or “CIPC”) – Further to the Company’s news releases of May 24, June 1 and July 6, 2017, CIPC is pleased to announce that it has closed its non-brokered private placement (the “Private Placement”) and has raised $225,000 by the issuance of 4,500,000 units (the “Units”) at $0.05 per Unit. Each Unit consists of one common share and one share purchase warrant, with each warrant entitling the holder to purchase an additional common share for a period of one year at an exercise price of $0.10. Finders’ fees in the amount of $10,000 were paid in connection with this Private Placement. All of the securities issued pursuant to the Private Placement are subject to a hold period expiring on November 29, 2017.

The Company intends to use the proceeds from this Private Placement for financing the continued development and pursuit of business opportunities in the area of pharmaceutical and neutraceutical manufacturing and distribution and for general working capital purposes.

Mehrun Payravi, the President and a Director of the Company, purchased, directly or indirectly, 1,000,000 Units for investment purposes pursuant to the Private Placement. Following closing of the Private Placement, Mr. Payravi holds 4,000,000 common shares representing approximately 10.7% of the outstanding common shares of the Company. In addition, Mr. Payravi holds stock options to purchase an additional 300,000 common shares of the Company and also holds warrants for the purchase of an additional 1,000,000 common shares. If these stock options and warrants were exercised in full, Mr. Payravi would own, directly and indirectly, 5,300,000 common shares of the Company representing approximately 13.7% of the Company’s then issued and outstanding common shares, assuming no other shares of the Company are issued. Mr. Payravi acquired these Units for investment purposes and may, from time to time, acquire additional securities of the Company or dispose of such securities as he may deem appropriate. For the purposes of National Instrument 62-103 early warning reporting, the address of Mr. Payravi is 2489 Bellevue Avenue, West Vancouver, British Columbia V7V 1E1. A copy of the early warning report being filed by Mr. Payravi may be obtained by contacting the Company at (604) 922-2030.

Douglas Mason, the CEO and a Director of the Company, purchased, directly or indirectly, 1,000,000 Units for investment purposes pursuant to the Private Placement. Following closing of the Private Placement, Mr. Mason holds 1,895,560 common shares representing approximately 5.07% of the outstanding common shares of the Company. In addition, Mr. Mason holds stock options to purchase an additional 405,000 common shares of the Company and also holds warrants for the purchase of an additional 1,166,667 common shares. If these stock options and warrants were exercised in full, Mr. Mason would own, directly and indirectly, 3,467,227 common shares of the Company representing approximately 8.9% of the Company’s then issued and outstanding common shares, assuming no other shares of the Company are issued. Mr. Mason acquired these Units for investment purposes and may, from time to time, acquire additional securities of the Company or dispose of such securities as he may deem appropriate. For the purposes of National Instrument 62-103 early warning reporting, the address of Mr. Mason is 2489 Bellevue Avenue, West Vancouver, British Columbia V7V 1E1. A copy of the early warning report being filed by Mr. Mason may be obtained by contacting the Company at (604) 922-2030.

As referred to above, certain directors of the Company acquired Units under the Private Placement. Such participation is considered to be a “related party transaction”, as defined under Multilateral Instrument 61-101 (“MI 61-101”). The Company intends to rely on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(1)(a) of MI 61-101 in respect of such insider participation.

About Canadian International Pharma Corp.

Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales. In 2016, CIPC launched its PharmaCert Program. PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets.

For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at www.canpharmacorp.ca.

CANADIAN INTERNATIONAL PHARMA CORP.

“Douglas L. Mason”

____________________________________________ Douglas L. Mason, Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.

FORWARD LOOKING STATEMENTS

This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. All statements, other than statements of historical facts, that address such matters, including the finder’s fee that may be paid by the Company and the intended use of proceeds of the private placement, are forward-looking statements. Forward-looking statements are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made and are subject to change after that date and the Company does not undertake any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.